The Journal of antimicrobial chemotherapy · 2026
In vivo PK/PD integration of p-furoylamphenmulin against Mycoplasma pneumoniae and its anti-inflammatory efficacy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xia Xirui, Zhou Xiaoyu, Chen Bingyi, Liang Weifeng, Deng Liyin, Bai Mingyang, Tang Youzhi, Ding Huanzhong
Аннотация
BACKGROUND AND OBJECTIVES: Mycoplasma pneumoniae is the primary pathogen of community-acquired bacterial pneumonia in humans. Children and adolescents are particularly susceptible, and a dry cough is the most common clinical symptom. In severe cases, this may progress to acute respiratory distress syndrome. To determine the anti-M. pneumoniae and anti-inflammatory activities of a novel pleuromutilin derivative, 22-(4-((2-furan-1-yl)acetamido)phenyl)thio) deoxypleuromutilin (p-furoylamphenmulin, or PFAPM).
METHODS: We utilized M. pneumoniae-infected mice to conduct in vivo pharmacokinetic (PK) and pharmacodynamic (PD) studies. The recommended dose was calculated based on PK/PD analysis, and treatment trials were performed at this dose to validate the fitted outcomes and investigate the anti-inflammatory effects.
RESULTS: The PK/PD results indicated that PFAPM exhibited an absorption half-life (T1/2ka) of 0.07 h and an elimination half-life (T1/2kel) of 0.87 h, with corresponding AUC values ranging from 1.18 to 8.33 μg·h/mL at doses of 10-80 mg/kg. When the mycoplasma load decreased by 3 log10 cfu/mL, the corresponding AUC48h/MIC and Cmax/MIC values were 7617.62 h and 1256.76, respectively, at a dose of 67.66 mg/kg. ELISA and flow cytometry analysis revealed that drug treatment significantly reduced cytokines and inflammatory cells associated with T helper 1 (Th1) and T helper 2 (Th2) immune responses.
CONCLUSIONS: AUC48h/MIC was the best parameter to describe the PK/PD relationship. The bactericidal effect was achieved at a dose of 67.66 (∼68) mg/kg. Pleuromutilins can reduce Th1 and Th2 inflammation.
METHODS: We utilized M. pneumoniae-infected mice to conduct in vivo pharmacokinetic (PK) and pharmacodynamic (PD) studies. The recommended dose was calculated based on PK/PD analysis, and treatment trials were performed at this dose to validate the fitted outcomes and investigate the anti-inflammatory effects.
RESULTS: The PK/PD results indicated that PFAPM exhibited an absorption half-life (T1/2ka) of 0.07 h and an elimination half-life (T1/2kel) of 0.87 h, with corresponding AUC values ranging from 1.18 to 8.33 μg·h/mL at doses of 10-80 mg/kg. When the mycoplasma load decreased by 3 log10 cfu/mL, the corresponding AUC48h/MIC and Cmax/MIC values were 7617.62 h and 1256.76, respectively, at a dose of 67.66 mg/kg. ELISA and flow cytometry analysis revealed that drug treatment significantly reduced cytokines and inflammatory cells associated with T helper 1 (Th1) and T helper 2 (Th2) immune responses.
CONCLUSIONS: AUC48h/MIC was the best parameter to describe the PK/PD relationship. The bactericidal effect was achieved at a dose of 67.66 (∼68) mg/kg. Pleuromutilins can reduce Th1 and Th2 inflammation.